Lyra Therapeutics Inc (NASDAQ: LYRA) on Tuesday, soared 4.66% from the previous trading day, before settling in for the closing price of $0.25. Within the past 52 weeks, LYRA’s price has moved between $0.21 and $6.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 58.51%. The company achieved an average annual earnings per share of -5.71%. With a float of $56.00 million, this company’s outstanding shares have now reached $57.21 million.
Let’s determine the extent of company efficiency that accounts for 88 employees. In terms of profitability, gross margin is -599.67%, operating margin of -4100.71%, and the pretax margin is -5567.64%.
Lyra Therapeutics Inc (LYRA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lyra Therapeutics Inc is 14.45%, while institutional ownership is 45.57%. The most recent insider transaction that took place on Nov 10 ’23, was worth 74,095. In this transaction Executive Chair of this company bought 25,000 shares at a rate of $2.96, taking the stock ownership to the 261,966 shares.
Lyra Therapeutics Inc (LYRA) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.27 earnings per share (EPS) for the period topping the consensus outlook (set at -0.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.60% during the next five years compared to -21.63% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Lyra Therapeutics Inc (LYRA) is currently performing well based on its current performance indicators. A quick ratio of 3.60 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.63, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Looking closely at Lyra Therapeutics Inc (NASDAQ: LYRA), its last 5-days average volume was 2.65 million, which is a jump from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 40.20%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 40.90%, which indicates a significant decrease from 58.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.44% in the past 14 days, which was higher than the 70.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2686, while its 200-day Moving Average is $2.2190. However, in the short run, Lyra Therapeutics Inc’s stock first resistance to watch stands at $0.2734. Second resistance stands at $0.2817. The third major resistance level sits at $0.2934. If the price goes on to break the first support level at $0.2534, it is likely to go to the next support level at $0.2417. Now, if the price goes above the second support level, the third support stands at $0.2334.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
Market capitalization of the company is 17.35 million based on 65,457K outstanding shares. Right now, sales total 1,560 K and income totals -62,680 K. The company made 600 K in profit during its latest quarter, and -48,130 K in sales during its previous quarter.
